Try the modernized beta website. Learn more about the modernization effort.
Working… Menu
Trial record 3 of 118 for:    FOCUS | Ovarian Cancer

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02641639
Recruitment Status : Terminated (Interim analysis failed to show efficacy benefit)
First Posted : December 29, 2015
Last Update Posted : March 22, 2018
Information provided by (Responsible Party):
Mateon Therapeutics

No Study Results Posted on for this Study
Recruitment Status : Terminated
Actual Primary Completion Date : October 2017
Actual Study Completion Date : October 2017